Annotation Detail
Information
- Associated Genes
- PON2
- Associated Variants
-
CCL11 p.Ala23Thr (p.A23T)
(
ENST00000305869.4 )
CCL11 p.Ala23Pro (p.A23P) ( ENST00000305869.4 )
PON2 p.Ser311Cys (p.S311C) ( ENST00000222572.8, ENST00000433091.6, ENST00000633192.1, ENST00000633531.1 )
ADRB3 p.Trp64Arg (p.W64R) ( ENST00000345060.5 )
CCL11 p.Ala23Thr (p.A23T) ( ENST00000305869.4 )
CCL11 p.Ala23Pro (p.A23P) ( ENST00000305869.4 )
PON2 p.Ser311Cys (p.S311C) ( ENST00000222572.8, ENST00000433091.6, ENST00000633192.1, ENST00000633531.1 )
ADRB3 p.Trp64Arg (p.W64R) ( ENST00000345060.5 ) - Associated Disease
- Diabetes
- Source Database
- DisGeNET
- Description
- In Cox regression model, after adjustment for baseline confounding variables including age, sex, smoking status, duration of diabetes, glycaemic control, lipid levels, waist circumference, blood pressure, albuminuria and estimated glomerular filtration rate, genetic variants, including Ala/Ala of SCYA11 (eotaxin) Ala23Thr, Cys/Cys or Cys/Ser of PON2 (paraoxonase 2) Ser311Cys and Arg/Arg of ADRB3 (beta3-adrenergic receptor) Trp64Arg, were independently associated with incident cardiac end-point, with respective hazard ratios (95% confidence interval) of 1.70 (1.10-2.61, P=0.037), 1.42 (1.08-1.88, P=0.013) and 3.84 (1.18-12.50, P=0.025).
- Pubmed
- 20536507
- Original source reporting the Gene Disease association
- BeFree
- DisGENET score for the Gene Disease association
- 0.00135720936040152
- Year of publication
- 2010
Drugs